Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies.

Aggarwal C, Gupta S, Hahn T, Smiley S, Padmanabhan S, McCarthy PL Jr, Battiwalla M.

Leuk Lymphoma. 2008 Aug;49(8):1494-500. doi: 10.1080/10428190802158453.

PMID:
18766961
2.

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori S, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y.

Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41. Epub 2007 May 29.

3.

Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.

Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.

Biol Blood Marrow Transplant. 2009 Feb;15(2):266-73. doi: 10.1016/j.bbmt.2008.11.029. Erratum in: Biol Blood Marrow Transplant. 2009 Apr;15(4):521.

4.

Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP.

Biol Blood Marrow Transplant. 2009 Feb;15(2):257-65. doi: 10.1016/j.bbmt.2008.11.025.

5.

Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence.

Battiwalla M, Hahn T, Radovic M, Roy H, Wahab A, Duman E, Bajwa R, Padmanabhan S, Becker J, Barrett AJ, McCarthy PL Jr.

Blood. 2006 Mar 1;107(5):1970-3. Epub 2005 Nov 10.

6.

Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.

Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.

Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17. doi: 10.1016/j.bbmt.2009.02.010. Epub 2009 Apr 9.

7.

High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia.

Xu LP, Luo XH, Chang YJ, Liu DH, Liu KY, Chen YH, Huang XJ.

Ann Hematol. 2009 Oct;88(10):1015-24. doi: 10.1007/s00277-009-0728-4. Epub 2009 Mar 25.

PMID:
19319533
8.

Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.

Schetelig J, Bornhäuser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H, Stelljes M, Hegenbart U, Schäfer-Eckart K, Füssel M, Wiedemann B, Thiede C, Kienast J, Baurmann H, Ganser A, Kolb HJ, Ehninger G.

J Clin Oncol. 2008 Nov 10;26(32):5183-91. doi: 10.1200/JCO.2007.15.5184. Epub 2008 Sep 2.

PMID:
18768435
9.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

10.

Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.

Gagne K, Busson M, Bignon JD, Balère-Appert ML, Loiseau P, Dormoy A, Dubois V, Perrier P, Jollet I, Bois M, Masson D, Moine A, Absi L, Blaise D, Charron D, Raffoux C; ARS2000 FRM and FGM group.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1366-75. doi: 10.1016/j.bbmt.2009.06.015.

11.

Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland.

Chalandon Y, Tiercy JM, Schanz U, Gungor T, Seger R, Halter J, Helg C, Chapuis B, Gratwohl A, Tichelli A, Nicoloso de Faveri G, Roosnek E, Passweg JR; Swiss Transplant Working Group for Blood and Marrow Transplantation (STABMT); Swiss National Donor Registry.

Bone Marrow Transplant. 2006 May;37(10):909-16.

PMID:
16565739
12.

Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.

Kato K, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, Shibuya T, Utsunomiya A, Kawase T, Kato S, Morishima Y, Kodera Y, Harada M; Japan Marrow Donor Program.

Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9.

13.

Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation.

Madrigal A, Shaw BE.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):40-3. Epub 2007 Oct 25.

PMID:
17964196
14.

A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.

Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, Hashino S, Morita R, Takahata M, Onozawa M, Kahata K, Kondo T, Ota S, Wakasa K, Sugita J, Koike T, Asaka M, Kasai M, Imamura M.

Biol Blood Marrow Transplant. 2008 Jul;14(7):817-23. doi: 10.1016/j.bbmt.2008.04.014. Erratum in: Biol Blood Marrow Transplant. 2008 Sep;14(9):1079.

15.

Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.

Hauzenberger D, Schaffer M, Ringdén O, Hassan Z, Omazic B, Mattsson J, Wikström AC, Remberger M.

Tissue Antigens. 2008 Dec;72(6):549-58. doi: 10.1111/j.1399-0039.2008.01148.x. Epub 2008 Oct 18.

PMID:
19000143
16.

Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation.

Danzer M, Polin H, Pröll J, Haunschmid R, Hofer K, Stabentheiner S, Hackl C, Kasparu H, König J, Hauser H, Binder M, Weiss R, Gabriel C, Krieger O.

Transplantation. 2009 Aug 27;88(4):528-32. doi: 10.1097/TP.0b013e3181b0e79e.

PMID:
19696636
17.
18.

Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.

Zhu KE, Hu JY, Zhang T, Chen J, Zhong J, Lu YH.

Eur J Haematol. 2008 Dec;81(6):461-6. doi: 10.1111/j.1600-0609.2008.01149.x. Epub 2008 Sep 4.

PMID:
18774951
19.

Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.

Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.

Biol Blood Marrow Transplant. 2009 Jan;15(1):61-72. doi: 10.1016/j.bbmt.2008.10.025.

20.

[Allogeneic hematopoietic stem cell transplantation from HLA one-locus-mismatched related donors].

Hyo R, Taguchi J, Kamijo A, Tanaka M, Hashimoto C, Kanamori H, Motomura S, Maruta A, Ishigatsubo Y.

Gan To Kagaku Ryoho. 2009 Nov;36(11):1845-9. Japanese.

PMID:
19920386

Supplemental Content

Support Center